China’s First: Meio Cardinav Medical’s Innovative Cardiac Electrophysiology Interventional Surgery Control System “TITIAN” Approved for Market Launch
November 14, 2025
On October 31st, the Cardiac Electrophysiology Interventional Surgery Control System, branded as “TITIAN” developed by Meio Cardinav Medical, received market approval from the NMPA. This milestone marks a groundbreaking achievement in China’s cardiac interventional field.
“TITIAN” is the first cardiac interventional surgical robot in China to complete multi-center clinical trials and gain approval. It is designed to work in conjunction with 3D mapping systems, such as Carto, for the treatment of cardiac arrhythmias, particularly atrial fibrillation (AF). The system is cited as being more advanced, precise, and safer than traditional methods.
System Composition and Usage
The product comprises an Actuator (including a front mechanical arm, front drive platform, rear mechanical arm, and rear drive platform), an Operator, and a Workstation. When used with a disposable component for the Electrophysiology Interventional Device Control System, “TITIAN” assists clinicians during radiofrequency catheter ablation procedures for atrial fibrillation by controlling compatible pressure-monitoring radiofrequency ablation catheters and sheaths.
Technical Highlights and Product Features
“TITIAN” is designed to perfectly address the limitations of manual instrument operation and the lengthy learning curve associated with traditional methods. It frees the surgeon’s hands, allows for the 100% reproduction of classic clinical procedures via a joystick, and enables remote ablation surgery from outside the catheter lab, significantly reducing X-ray radiation exposure.
Publicly available data indicate that this robotic system offers three key advantages compared to traditional manual operation:
- Dual-Arm Linkage for Easy Control: The system is the first to translate the synergistic operation of a physician’s two hands into a surgical robot. It supports the linked movement of dual mechanical arms, allowing for the integrated operation of the electrophysiology guiding sheath and the ablation catheter.
- Remote Scenario-Based Surgery for Enhanced Safety: By adopting a remote control system to perform electrophysiology catheter ablation, it replaces the traditional method where the surgeon manually operates the catheter and sheath bedside. During the procedure, the system provides a real-time graphical display of the catheter-sheath relationship, leading to better surgical safety.
- 5.2% Reduction in Recurrence Rate for Greater Efficacy: Follow-up data on the 12-month clinical recurrence rate for atrial fibrillation shows that robotic surgery reduced the recurrence rate by 5.2% compared to manual surgery. The stability of the contact between the interventional catheter and cardiac tissue is improved by an order of magnitude. In intervention and ablation surgeries performed on a beating heart, the surgical robot significantly reduces pressure fluctuations, enhancing operational stability.
Disclaimer: The information on this platform is for informational purposes only and is based on publicly available sources, such as official press releases and regulatory databases. While we strive for accuracy, details may vary from the manufacturer’s official statements, particularly if they have been translated. We encourage readers to consult the manufacturer’s official website and communications for the most current and accurate information. This report is not a substitute for professional medical advice, diagnosis, or treatment and does not constitute an endorsement of any product or company. We do not accept responsibility for any errors, omissions, or actions taken based on the information provided.